Randomized, double-blind, placeb-controlled study of AMG0001 (HGF plasmid) for patients with arterioscleosis obliterans

Trial Profile

Randomized, double-blind, placeb-controlled study of AMG0001 (HGF plasmid) for patients with arterioscleosis obliterans

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2013

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Arteriosclerosis obliterans
  • Focus Therapeutic Use
  • Sponsors AnGes MG
  • Most Recent Events

    • 28 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top